ATE173024T1 - In der therapie von einer hiv-1-infektion verwendbare monoklonale antikörper - Google Patents

In der therapie von einer hiv-1-infektion verwendbare monoklonale antikörper

Info

Publication number
ATE173024T1
ATE173024T1 AT92919658T AT92919658T ATE173024T1 AT E173024 T1 ATE173024 T1 AT E173024T1 AT 92919658 T AT92919658 T AT 92919658T AT 92919658 T AT92919658 T AT 92919658T AT E173024 T1 ATE173024 T1 AT E173024T1
Authority
AT
Austria
Prior art keywords
hiv
infection
monoclonal antibodies
protein
capacity
Prior art date
Application number
AT92919658T
Other languages
English (en)
Inventor
Tsuneya Ohno
Original Assignee
Nissin Food Products Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissin Food Products Ltd filed Critical Nissin Food Products Ltd
Application granted granted Critical
Publication of ATE173024T1 publication Critical patent/ATE173024T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT92919658T 1991-08-22 1992-08-24 In der therapie von einer hiv-1-infektion verwendbare monoklonale antikörper ATE173024T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74856291A 1991-08-22 1991-08-22

Publications (1)

Publication Number Publication Date
ATE173024T1 true ATE173024T1 (de) 1998-11-15

Family

ID=25009973

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92919658T ATE173024T1 (de) 1991-08-22 1992-08-24 In der therapie von einer hiv-1-infektion verwendbare monoklonale antikörper

Country Status (9)

Country Link
EP (1) EP0554446B1 (de)
JP (1) JP2888980B2 (de)
KR (1) KR100251823B1 (de)
AT (1) ATE173024T1 (de)
AU (1) AU659677B2 (de)
CA (1) CA2094611C (de)
DE (1) DE69227500T2 (de)
RU (1) RU2128222C1 (de)
WO (1) WO1993004090A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2888981B2 (ja) * 1992-08-24 1999-05-10 日清食品株式会社 Ｈｉｖ免疫療法
US6114143A (en) * 1993-03-11 2000-09-05 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Anti-HIV monoclonal antibody
KR100304333B1 (ko) * 1993-08-24 2001-11-30 안도 고끼 재조합의사람화된항-사람면역결핍바이러스항체
US5618922A (en) * 1994-07-25 1997-04-08 Nissin Shokuhin Kabushiki Kaisha NM03 antibody materials and methods
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
EP1980617A1 (de) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
AU2596600A (en) 1998-12-31 2000-07-31 Chiron Corporation Modified hiv env polypeptides
CN1339319A (zh) * 2000-08-18 2002-03-13 清华大学 一种治疗艾滋病的药物及其制备方法
CA2441287C (en) 2001-03-22 2014-06-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE122237T1 (de) * 1987-05-29 1995-05-15 Tanox Biosystems Inc Hiv-1 neutralisierende monoklonale antikörper.
DE3885355T2 (de) * 1987-05-29 1994-06-01 Shuzo Matsushita Monoklonale Antikörper.
EP0339504A3 (de) * 1988-04-26 1990-09-12 The Du Pont Merck Pharmaceutical Company Menschliches immunoinsuffizientes Virus (HIV) env-codiertes Peptid, welches im Stande ist, die HIV hemmenden Antikörper bei Säugetieren hervorzurufen
PT94276A (pt) * 1989-06-05 1991-02-08 Anticorpo monoclonal capaz de neutralizar o prototipo mn de hiv
AU8228791A (en) * 1990-06-15 1992-01-07 New York University Heterohybridomas producing human monoclonal antibodies to hiv-1
JP2989862B2 (ja) * 1990-07-02 1999-12-13 財団法人化学及血清療法研究所 モノクローナル抗体
RU2070926C1 (ru) * 1993-04-19 1996-12-27 Валерий Борисович Локтев Штамм гибридных культивируемых клеток mus musculus l., используемый для получения моноклональных антител к с-концевой части белка р 24 вируса иммунодефицита человека типа i

Also Published As

Publication number Publication date
RU2128222C1 (ru) 1999-03-27
EP0554446B1 (de) 1998-11-04
AU659677B2 (en) 1995-05-25
JP2888980B2 (ja) 1999-05-10
DE69227500T2 (de) 1999-04-15
EP0554446A1 (de) 1993-08-11
DE69227500D1 (de) 1998-12-10
WO1993004090A1 (en) 1993-03-04
CA2094611C (en) 2000-07-25
AU2568392A (en) 1993-03-16
JPH06503970A (ja) 1994-05-12
CA2094611A1 (en) 1993-02-23
KR930702509A (ko) 1993-09-09
EP0554446A4 (de) 1994-02-09
KR100251823B1 (ko) 2000-04-15

Similar Documents

Publication Publication Date Title
DE69227500D1 (de) In der Therapie von einer HIV-1-Infektion verwendbare monoklonale Antikörper
JPH06502539A (ja) Ｈｉｖ−１　ｇｐ１２０のｖ３ループおよびｃｄ−４結合部位に特異的な中和ヒトモノクローナル抗体
AT398080B (de) Immortalisierte zellinie, verfahren zu ihrer herstellung und verfahren zur herstellung von monoklonalen antikörpern sowie diagnoseverfahren und -mittel
ATE122237T1 (de) Hiv-1 neutralisierende monoklonale antikörper.
RU93005284A (ru) Моноклональные антитела линии клеток, фармацевтические композиции, способы лечения, фрагмент антитела
US5854400A (en) Monoclonal antibodies which neutralize HIV-1 infection
JP2004518624A5 (de)
US5834599A (en) Immunoconjugates which neutralize HIV-1 infection
CA2170034A1 (en) Recombinant humanized anti-human immunodeficiency virus antibody
MC2308A1 (fr) Peptides utilises dans la vaccination et l'induction d'anticorps neutralisant contre le virus de l'immunodeficience humaine
ATE135743T1 (de) Monoklonale menschliche antikörper gegen hiv-i
US6241986B1 (en) Human monoclonal antibodies to the CD4-binding domain of HIV, uses thereof and synergistic neutralization of HIV
JPH11501310A (ja) レトロウイルスの調節タンパク質から誘導された無毒の免疫原、抗体、製造方法およびそれらを含んでなる医薬組成物
SE9000333D0 (sv) Monoklonal antikropp
US5445960A (en) Monoclonal antibodies specific for HIV and hybridomas for their production
KR0149848B1 (ko) Hiv에 특이한 모노클로날 항체 및 그 제조용 하이브리도마
AU8010791A (en) Hiv monoclonal antibody
US6124132A (en) Use of anti-HIV IGA antibodies for producing immunological protection against the human immunodeficiency virus
US6200575B1 (en) Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
ATE201698T1 (de) Immuntherapeutika gegen hiv
KR890009415A (ko) 항 비루스성 화합물 및 그 제조방법
RU94024562A (ru) Антитело, полинуклеотид, клетка, способ получения антитела
KR100871455B1 (ko) Ｈｉｖ 바이러스에 대한 천연 항체
CA2028121A1 (en) Human monoclonal antibodies to human immunodeficiency virus
Ohno HIV immunotherapeutics

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee